{"title":"循环中的 FGF-23 与血液透析患者骨质疏松症和骨折风险增加有关：一项前瞻性观察研究","authors":"Dong Liu, Hongyan Yang, Qirong Liao, Baocao Chang, Weiwei Zhang, Xiaoxiong Li, Jinping Li, Mingliang Hou, Linqiu Ma, Yating Liu, Jing Lu, Rui Zhou","doi":"10.1155/2024/1070492","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Background and Objective:</b> It is still controversial whether circulating fibroblast growth factor 23 (FGF-23) can be used as a biomarker for the diagnosis of osteoporosis and fractures in patients with chronic kidney disease undergoing hemodialysis. We investigated the association of circulating FGF-23 concentrations with an increased risk of osteoporosis and fractures of hemodialysis patients in the prospective study.</p>\n <p><b>Methods:</b> These data were collected in adult patients with hemodialysis in China from January 1 to December 30, 2016, and patients were followed up for 3.5 years. The association of circulating FGF-23 with the risk of osteoporosis and fractures was analyzed by multivariate analysis.</p>\n <p><b>Results:</b> The study included 1788 hemodialysis patients, with a median age of 56 years (50–64 years) and a female population of 54.5%. Of 1788 patients, 389 (21.8%) developed osteoporosis and 207 (11.6%) developed fractures. High concentrations of FGF-23 were significantly related to osteoporosis and fractures and were significantly related to different types of fractures (vertebral fractures, nonvertebral fractures, and hip fractures). Adjusted for all potential risk factors, high concentrations of FGF-23 were associated with the risk of osteoporosis or fractures.</p>\n <p><b>Conclusion:</b> High concentrations of circulating FGF-23 were associated with the risk of osteoporosis and fractures, including vertebral fractures and hip fractures. FGF-23, along with bALP, CTX, and OC, may be used as a serum biomarker for predicting the risk of osteoporosis and fractures in patients with hemodialysis.</p>\n </div>","PeriodicalId":13782,"journal":{"name":"International Journal of Clinical Practice","volume":"2024 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/1070492","citationCount":"0","resultStr":"{\"title\":\"Circulating FGF-23 Is Associated With Increased Risk of Osteoporosis and Fractures in Hemodialysis Patients: A Prospective Observational Study\",\"authors\":\"Dong Liu, Hongyan Yang, Qirong Liao, Baocao Chang, Weiwei Zhang, Xiaoxiong Li, Jinping Li, Mingliang Hou, Linqiu Ma, Yating Liu, Jing Lu, Rui Zhou\",\"doi\":\"10.1155/2024/1070492\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><b>Background and Objective:</b> It is still controversial whether circulating fibroblast growth factor 23 (FGF-23) can be used as a biomarker for the diagnosis of osteoporosis and fractures in patients with chronic kidney disease undergoing hemodialysis. We investigated the association of circulating FGF-23 concentrations with an increased risk of osteoporosis and fractures of hemodialysis patients in the prospective study.</p>\\n <p><b>Methods:</b> These data were collected in adult patients with hemodialysis in China from January 1 to December 30, 2016, and patients were followed up for 3.5 years. The association of circulating FGF-23 with the risk of osteoporosis and fractures was analyzed by multivariate analysis.</p>\\n <p><b>Results:</b> The study included 1788 hemodialysis patients, with a median age of 56 years (50–64 years) and a female population of 54.5%. Of 1788 patients, 389 (21.8%) developed osteoporosis and 207 (11.6%) developed fractures. High concentrations of FGF-23 were significantly related to osteoporosis and fractures and were significantly related to different types of fractures (vertebral fractures, nonvertebral fractures, and hip fractures). Adjusted for all potential risk factors, high concentrations of FGF-23 were associated with the risk of osteoporosis or fractures.</p>\\n <p><b>Conclusion:</b> High concentrations of circulating FGF-23 were associated with the risk of osteoporosis and fractures, including vertebral fractures and hip fractures. FGF-23, along with bALP, CTX, and OC, may be used as a serum biomarker for predicting the risk of osteoporosis and fractures in patients with hemodialysis.</p>\\n </div>\",\"PeriodicalId\":13782,\"journal\":{\"name\":\"International Journal of Clinical Practice\",\"volume\":\"2024 1\",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/1070492\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2024/1070492\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/1070492","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Circulating FGF-23 Is Associated With Increased Risk of Osteoporosis and Fractures in Hemodialysis Patients: A Prospective Observational Study
Background and Objective: It is still controversial whether circulating fibroblast growth factor 23 (FGF-23) can be used as a biomarker for the diagnosis of osteoporosis and fractures in patients with chronic kidney disease undergoing hemodialysis. We investigated the association of circulating FGF-23 concentrations with an increased risk of osteoporosis and fractures of hemodialysis patients in the prospective study.
Methods: These data were collected in adult patients with hemodialysis in China from January 1 to December 30, 2016, and patients were followed up for 3.5 years. The association of circulating FGF-23 with the risk of osteoporosis and fractures was analyzed by multivariate analysis.
Results: The study included 1788 hemodialysis patients, with a median age of 56 years (50–64 years) and a female population of 54.5%. Of 1788 patients, 389 (21.8%) developed osteoporosis and 207 (11.6%) developed fractures. High concentrations of FGF-23 were significantly related to osteoporosis and fractures and were significantly related to different types of fractures (vertebral fractures, nonvertebral fractures, and hip fractures). Adjusted for all potential risk factors, high concentrations of FGF-23 were associated with the risk of osteoporosis or fractures.
Conclusion: High concentrations of circulating FGF-23 were associated with the risk of osteoporosis and fractures, including vertebral fractures and hip fractures. FGF-23, along with bALP, CTX, and OC, may be used as a serum biomarker for predicting the risk of osteoporosis and fractures in patients with hemodialysis.
期刊介绍：
IJCP is a general medical journal. IJCP gives special priority to work that has international appeal.
IJCP publishes:
Editorials. IJCP Editorials are commissioned. [Peer reviewed at the editor''s discretion]
Perspectives. Most IJCP Perspectives are commissioned. Example. [Peer reviewed at the editor''s discretion]
Study design and interpretation. Example. [Always peer reviewed]
Original data from clinical investigations. In particular: Primary research papers from RCTs, observational studies, epidemiological studies; pre-specified sub-analyses; pooled analyses. [Always peer reviewed]
Meta-analyses. [Always peer reviewed]
Systematic reviews. From October 2009, special priority will be given to systematic reviews. [Always peer reviewed]
Non-systematic/narrative reviews. From October 2009, reviews that are not systematic will be considered only if they include a discrete Methods section that must explicitly describe the authors'' approach. Special priority will, however, be given to systematic reviews. [Always peer reviewed]
''How to…'' papers. Example. [Always peer reviewed]
Consensus statements. [Always peer reviewed] Short reports. [Always peer reviewed]
Letters. [Peer reviewed at the editor''s discretion]
International scope
IJCP publishes work from investigators globally. Around 30% of IJCP articles list an author from the UK. Around 30% of IJCP articles list an author from the USA or Canada. Around 45% of IJCP articles list an author from a European country that is not the UK. Around 15% of articles published in IJCP list an author from a country in the Asia-Pacific region.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
